Entera Bio
ENTX
15 hedge funds and large institutions have $9.75M invested in Entera Bio in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
37% more capital invested
Capital invested by funds: $7.11M → $9.75M (+$2.63M)
2.77% more ownership
Funds ownership: 12.01% → 14.78% (+2.8%)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.47M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$879K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38.9K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$33.4K |
| 5 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$27.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$49.8K |
| 2 |
Renaissance Technologies
New York
|
-$37.9K |
| 3 |
VF
Virtu Financial
New York
|
-$37K |
| 4 |
Millennium Management
New York
|
-$32.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20.9K |
ENTX Hedge Fund Activity: Q2 2024 in Review
15 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q2 2024, worth a combined $9.75M — up 37% from $7.11M a quarter earlier.
Fund positioning in ENTX was balanced in Q2 2024: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $1.47M. The largest seller was Susquehanna International Group, cutting an estimated $49.8K.
- 15 institutional investors held Entera Bio (ENTX) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $9.75M of Entera Bio stock for Q2 2024, up 37% quarter-over-quarter.
- 5 funds opened new Entera Bio positions in Q2 2024 and 5 closed out, a net change of 0 holders.
- The largest Entera Bio buyer in Q2 2024 was Schonfeld Strategic Advisors, an estimated $1.47M added.
- The largest Entera Bio seller in Q2 2024 was Susquehanna International Group, an estimated $49.8K sold.
Based on aggregated 13F filings for Q2 2024.